Biological potency and contents in group 1 and group 2 allergen of two batches of Orylmyte 300 IR and two batches of Acarizax 12 SQ-HDM, and the corresponding ratios as compared to ratios obtainable from literature
Product
Orylmyte 300 IR
Acarizax 12 SQ-HDM
Ratio between Orylmyte 300 IR and Acarizax 12 SQ-HDM obtained from this study
Ratio between Orylmyte 300 IR and Acarizax 12 SQ-HDM obtained from literature*
2028296281 (batch number)
2028373615 (batch number)
Mean
4306178 (batch number)
4306183 (batch number)
Mean
Biological potency (IR/tablet)
292
296
294
110
107
109
2.7
2.9
Der p 1 (µg/tablet)
11.5
12.5
12.0
4.6
4.1
4.4
2.8
2.2
Der f 1 (µg/tablet)
43.1
44.5
43.8
8.2
9.5
8.9
4.9
5.1
Der p 2 + Der f 2 (µg/tablet)
8.5
7.1
7.8
6.8
7.0
6.9
1.1
0.9
* The ratio in terms of biological potency, as expressed in Japanese AU (JAU) [11], as well as the ratios in terms of Der p 1, Der f 1, and group 2 allergens, are directly obtainable from Ohashi-Doi et al. [10]
TB and LM: Conceptualization, Writing—original draft. SD, MR, KJ, CP, and MD: Formal analysis. SV: Supervision. HC and CD: Supervision, Writing—review & editing.
Conflicts of interest
All authors are employees of Stallergenes Greer, Antony, France.
Ethical approval
Individual sera constituting the pool, used as a reagent, come from blood donation at the French Blood Establishment (EFS) holding an Ethics and Professional conduct committee as per the decision n° 2019-05.
Consent to participate
Informed consent to participate in the study was obtained from all participants.
Consent to publication
Not applicable.
Availability of data and materials
The data supporting our findings will not be shared because they are proprietary.
Pfaar O, Bousquet J, Durham SR, Kleine-Tebbe J, Larche M, Roberts G, et al. One hundred and ten years of Allergen Immunotherapy: a journey from empiric observation to evidence.Allergy. 2022;77:454–68. [DOI] [PubMed]
Palomares O, Akdis M, Martín-Fontecha M, Akdis CA. Mechanisms of immune regulation in allergic diseases: the role of regulatory T and B cells.Immunol Rev. 2017;278:219–36. [DOI] [PubMed]
Zimmer J, Bonertz A, Vieths S. Quality requirements for allergen extracts and allergoids for allergen immunotherapy.Allergol Immunopathol (Madr). 2017;45:4–11. [DOI] [PubMed]
Larenas-Linnemann D, Esch R, Plunkett G, Brown S, Maddox D, Barnes C, et al. Maintenance dosing for sublingual immunotherapy by prominent European allergen manufacturers expressed in bioequivalent allergy units.Ann Allergy Asthma Immunol. 2011;107:448–58.E3. [DOI] [PubMed]
Larenas-Linnemann D, Cox LS; Immunotherapy and Allergy Diagnostics Committee of the American Academy of Allergy, Asthma and Immunology. European allergen extract units and potency: review of available information.Ann Allergy Asthma Immunol. 2008;100:137–45. [DOI] [PubMed]
Batard T, Canonica WG, Pfaar O, Shamji MH, O’Hehir RE, van Zelm MC, et al. Current advances in house dust mite allergen immunotherapy (AIT): routes of administration, biomarkers and molecular allergen profiling.Mol Immunol. 2023;155:124–34. [DOI] [PubMed]
Hrabina M, Purohit A, Oster JP, Papanikolaou I, Jain K, Pascal P, et al. Standardization of an ash (Fraxinus excelsior) pollen allergen extract.Int Arch Allergy Immunol. 2007;142:11–8. [DOI] [PubMed]
Kjeldahl J. Neue methode zur bestimmung des stickstoffs in organischen körpern.Z Anal Chem. 1883;22:366–82. German. [DOI]
Batard T, Nony E, Hrabina M, Chabre H, Frati F, Moingeon P. Advances in the quantification of relevant allergens in allergenic extracts.Eur Ann Allergy Clin Immunol. 2013;45:33–7.
Ohashi-Doi K, Kito H, Du W, Nakazawa H, Ipsen H, Gudmann P, et al. Bioavailability of house dust mite allergens in sublingual allergy tablets is highly dependent on the formulation.Int Arch Allergy Immunol. 2017;174:26–34. [DOI] [PubMed]
Takai T, Okamoto Y, Okubo K, Nagata M, Sakaguchi M, Fukutomi Y, et al. Japanese Society of Allergology task force report on standardization of house dust mite allergen vaccines – secondary publication.Allergol Int. 2015;64:181–6. [DOI] [PubMed]
Posa D, Perna S, Resch Y, Lupinek C, Panetta V, Hofmaier S, et al. Evolution and predictive value of IgE responses toward a comprehensive panel of house dust mite allergens during the first 2 decades of life.J Allergy Clin Immunol. 2017;139:541–9.E8. [DOI] [PubMed]
Potapova E, Bordas-Le Floch V, Schlederer T, Vrtala S, Huang HJ, Canonica GW, et al. Molecular reactivity profiling upon immunotherapy with a 300 IR sublingual house dust mite tablet reveals marked humoral changes towards major allergens.Allergy. 2022;77:3084–95. [DOI] [PubMed]
Li YF, Arnold RJ, Tang H, Radivojac P. The importance of peptide detectability for protein identification, quantification, and experiment design in MS/MS proteomics.J Proteome Res. 2010;9:6288–97. [DOI] [PubMed] [PMC]
Batard T, Hrabina A, Bi XZ, Chabre H, Lemoine P, Couret MN, et al. Production and proteomic characterization of pharmaceutical-grade Dermatophagoides pteronyssinus and Dermatophagoides farinae extracts for allergy vaccines.Int Arch Allergy Immunol. 2006;140:295–305. [DOI] [PubMed]
